ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale

Background The ALS Functional Rating Scale in its revised version (ALSFRS-R) is a disease-specific severity score that reflects motor impairment and functional deterioration in people with amyotrophic lateral sclerosis (ALS).

It has been widely applied in both clinical practice and ALS research.

However, in Germany, several variants of the scale, each differing slightly from the others, have developed over time and are currently in circulation.

This lack of uniformity potentially hampers data interpretation and may decrease item validity.

Furthermore, shortcomings within the standard ALSFRS-R questions and answer options can limit the quality and conclusiveness of collected data.

Methods In a multistage consensus-building process, 18 clinical ALS experts from the German ALS/MND network analyzed the ALSFRS-R in its current form and created an adapted, annotated, and revised scale that closely adheres to the well-established standardized English version.

Results Ten German-language variants of the ALSFRS-R were collected, three of which contained instructions for self-assessment.

All of these variants were compiled and a comprehensive linguistic revision was undertaken.

A short introduction was added to the resulting scale, comprising general instructions for use and explanations for each of the five reply options per item.

This adapted version of the scale, named ALSFRS-R-SE (with the “SE” referring to “self-explanatory”), was carefully reviewed for language and comprehensibility, in both German and English.

Conclusion An adapted and annotated version of the ALSFRS-R scale was developed through a multistage consensus process.

The decision to include brief explanations of specific scale items and reply options was intended to facilitate ALSFRS-R-SE assessments by both healthcare professionals and patients.

Further studies are required to investigate the accuracy and utility of the ALSFRS-R-SE in controlled trials and clinical real-world settings.